Biotech IPO market still in flux following flashy Friday tripleheader
Three clinical-stage biotechs, three upsized offerings and three first-day share spikes.
Last Friday’s biotech IPO tripleheader was a multiyear rarity for an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
